<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />



<meta name="date" content="2026-02-13" />

<title>LAURUSLABS</title>

<script src="rmdlib/header-attrs-2.30/header-attrs.js"></script>
<script src="rmdlib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="rmdlib/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="rmdlib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="rmdlib/navigation-1.1/tabsets.js"></script>
<script src="rmdlib/accessible-code-block-0.0.1/empty-anchor.js"></script>
<link href="rmdlib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="rmdlib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<meta name="description" content="Indian equities analysis, margin reports, risk, etc..." />
<meta property="og:image" content="https://avatars3.githubusercontent.com/u/21966469?s=400&v=4" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>










<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">StockViz</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-globe"></span>
     
    Macro
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-bnd.html">Fixed Income</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cur.html">Currencies</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cmdy.html">Commodities</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-arrows-v"></span>
     
    52w H&amp;L
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-rocket"></span>
     
    ATH
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-magnet"></span>
     
    Drawdowns
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-train"></span>
     
    Streaks
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-hand-pointer-o"></span>
     
    Indian Indices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-risk.html">Performance Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-IN.html">Index Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-MKT-CAP.html">Classification Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-industry.html">Industry Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-syn.html">Synthetic Indices</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-vol-NIFTY.html">NIFTY Volatility</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-valuations.html">Valuations</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/results-IN.html">Result Dates</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/eq-in/rp-margin.html">Margin Report</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-shopping-bag"></span>
     
    Funds
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports03/mf/rp-IN.html">Indian Mutual Funds</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports03/pms/rp-IN.html">Indian PMS</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-risk.html">US ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-sector.html">US Sector ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-country.html">Country $ ETFs</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-percent"></span>
     
    Fama-French
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-industry.html">Industry</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-factors.html">Factors</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-regression.html">Regressions</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://stockviz.biz">
    <span class="fa fa-home"></span>
     
  </a>
</li>
<li>
  <a href="https://stockviz.substack.com">
    <span class="fa fa-envelope-o"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">LAURUSLABS</h1>
<h3 class="subtitle">Equity Metrics</h3>
<h4 class="date">February 13, 2026</h4>

</div>


<div id="laurus-labs-limited" class="section level1">
<h1>Laurus Labs Limited</h1>
<p><a href="/reports01/index/industry/rp-Pharmaceuticals.html">Pharmaceuticals</a></p>
<div id="annual-returns" class="section level2">
<h2>Annual Returns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.LAURUSLABS.fan.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.LAURUSLABS.annret.png" /></p>
</div>
<div id="cumulative-returns-and-drawdowns" class="section level2">
<h2>Cumulative Returns and Drawdowns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.LAURUSLABS.cumret.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.LAURUSLABS.sma.cumret.png" /></p>
<p><br><br></p>
</div>
<div id="fundamentals" class="section level2">
<h2>Fundamentals</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.LAURUSLABS.eps.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.LAURUSLABS.RevenueFromOperations.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.LAURUSLABS.ebit.png" /></p>
<p><br><br></p>
</div>
<div id="ownership" class="section level2">
<h2>Ownership</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.LAURUSLABS.ownership.png" /></p>
<p><br><br></p>
</div>
<div id="margined" class="section level2">
<h2>Margined</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.LAURUSLABS.mtf.png" /></p>
<p><br><br></p>
<p><br />
</p>
</div>
<div id="ai-summary" class="section level2">
<h2>AI Summary</h2>
<p><em>asof: 2025-12-03 </em></p>
<div id="laurus-labs-limited-lauruslabs-analysis" class="section level3">
<h3>Laurus Labs Limited (LAURUSLABS) Analysis</h3>
<p><strong>Overview</strong>: Laurus Labs, a leading Indian pharma player focused on APIs, FDFs (Generics), and CDMO (small molecules, bio/large molecules, advanced therapies), reported stellar H1 FY26 results (ended Sep 30, 2025): Revenues +33% YoY to ₹3,223 Cr, EBITDA +132% to ₹818 Cr (25.4% margins, +10.8% pts YoY), Net Profit +985% to ₹358 Cr. Q2 FY26 showed acceleration (Revenues +35% YoY to ₹1,653 Cr, EBITDA +136% to ₹429 Cr at 26.0% margins). Growth driven by CDMO (74% YoY) and Generics (20% YoY). Company declared ₹0.80/share interim dividend (40% payout). Capex at ₹489 Cr (15% of sales) supports expansion. Outlook positive with sustained momentum expected.</p>
<p>Below is a structured summary of <strong>tailwinds</strong>, <strong>headwinds</strong>, <strong>growth prospects</strong>, and <strong>key risks</strong> based on the provided documents (financial results, presentation, press release, board outcomes).</p>
<div id="tailwinds-positive-catalysts" class="section level6">
<h6><strong>Tailwinds (Positive Catalysts)</strong></h6>
<table>
<colgroup>
<col width="32%" />
<col width="36%" />
<col width="32%" />
</colgroup>
<thead>
<tr class="header">
<th>Factor</th>
<th>Details</th>
<th>Impact</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Robust Financial Momentum</strong></td>
<td>H1 Revenues +33%, EBITDA margins expanded 10.8% pts to 25.4%; Gross margins +4.5% pts to 59.6%. Q2 acceleration (+35% revenue growth). Strong OCF ₹1,093 Cr (+1,818% YoY). ROCE 16.3% (+10.7% pts). Net debt/EBITDA down to 1.3x.</td>
<td>High – Operational leverage from CDMO mix, better capacity utilization (asset turns recovering).</td>
</tr>
<tr class="even">
<td><strong>CDMO Strength</strong></td>
<td>Small molecules +88% H1 YoY (₹964 Cr); &gt;110 active pipeline projects. Bio Q2 +62% QoQ. Healthy big/mid-pharma client mix.</td>
<td>Medium-High – Core growth engine (32% of H1 revenues).</td>
</tr>
<tr class="odd">
<td><strong>Generics Resilience</strong></td>
<td>+20% H1 YoY (₹2,183 Cr); FDF +54%, API +3%. ARVs +21% (₹1,380 Cr). CMO ramp-up.</td>
<td>Medium – Stable base (68% revenues); developed market traction.</td>
</tr>
<tr class="even">
<td><strong>Strategic Expansions</strong></td>
<td>532-acre Vizag land (+US$600mn over 8 yrs); Gene/ADC facility (Hyderabad), Fermentation (Vizag), CMO oral solids on track. US$2mn in Aarvik (ADC tech). R&amp;D spends 4.3% of sales.</td>
<td>Medium – Positions for high-margin advanced modalities.</td>
</tr>
<tr class="odd">
<td><strong>ESG &amp; Quality</strong></td>
<td>S&amp;P DJSI “Industry Mover”; MSCI BBB (4 yrs); 65 audits passed (no criticals); GPW certified.</td>
<td>Low-Medium – Enhances global appeal, funding access.</td>
</tr>
<tr class="even">
<td><strong>Shareholder Returns</strong></td>
<td>Interim dividend ₹0.80/share; EPS ₹6.6 (+1,000% YoY).</td>
<td>Low – Signals confidence.</td>
</tr>
</tbody>
</table>
</div>
<div id="headwinds-challenges" class="section level6">
<h6><strong>Headwinds (Challenges)</strong></h6>
<table>
<colgroup>
<col width="32%" />
<col width="36%" />
<col width="32%" />
</colgroup>
<thead>
<tr class="header">
<th>Factor</th>
<th>Details</th>
<th>Impact</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>High Capex Intensity</strong></td>
<td>H1 Capex ₹489 Cr (15% sales); FY22-26 total ~₹3,600 Cr (85% API/CDMO). Ongoing expansions strain FCF if delays occur.</td>
<td>Medium – Debt/EBITDA manageable but rising if growth misses.</td>
</tr>
<tr class="even">
<td><strong>Segment Volatility</strong></td>
<td>Bio -8% H1 YoY (customer scale-up issues); CDMO lumpy (long lead times caused prior underutilization).</td>
<td>Medium – Offset by small molecules strength.</td>
</tr>
<tr class="odd">
<td><strong>Margin Pressure Risks</strong></td>
<td>Gross margins improved but dependent on mix; R&amp;D/capex sustained at 4-15%. Forex/competition in Generics.</td>
<td>Low-Medium – Current execution strong.</td>
</tr>
<tr class="even">
<td><strong>Pending Corporate Actions</strong></td>
<td>Demerger/amalgamation of LSPL pending NCLT approval (Appointed Date Apr 1, 2025); no financial impact yet.</td>
<td>Low – Simplifies structure but execution risk.</td>
</tr>
</tbody>
</table>
</div>
<div id="growth-prospects" class="section level6">
<h6><strong>Growth Prospects</strong></h6>
<table>
<colgroup>
<col width="32%" />
<col width="40%" />
<col width="27%" />
</colgroup>
<thead>
<tr class="header">
<th>Opportunity</th>
<th>Timeline/Scale</th>
<th>Potential</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>CDMO Ramp-Up</strong></td>
<td>FY26-27: Clinical/commercial deliveries; peptides/enzymatic/flow tech. &gt;90 human health projects. Fermentation Vizag ops by 2026-end.</td>
<td>High – 74% H1 growth; margins &gt;60%; asset turns to normalize in 24 months. Targets FY26 revenue &gt;₹6,500 Cr implied.</td>
</tr>
<tr class="even">
<td><strong>Advanced Modalities</strong></td>
<td>Gene/ADC GMP Hyderabad (2026-end, &gt;US$25mn capex); Cell therapy (NexCAR19 &gt;500 infusions; 2nd GMP Navi Mumbai Jan’26). Claudin18.2 patent.</td>
<td>High – Next-gen (ADC, CAR-T); ImmunoACT associate scaling.</td>
</tr>
<tr class="odd">
<td><strong>Generics/CMO</strong></td>
<td>FDF filings: 90 cumulative (US:45, EU:22); KRKA JV (Hyderabad ops mid-2027). CMO oral solids Vizag. DMF 91 filed.</td>
<td>Medium-High – ARV leadership + developed markets; full-yr API utilization visible.</td>
</tr>
<tr class="even">
<td><strong>Capacity/Mfg</strong></td>
<td>8,000 KL reactors; 9 CDMO sites; Vizag pharma complex (6,350 jobs). Integrated D&amp;M platform.</td>
<td>Medium – &gt;85% capex growth-focused; ROCE progression.</td>
</tr>
<tr class="odd">
<td><strong>Overall Outlook</strong></td>
<td>H1 momentum to continue; EBITDA margins to improve further on utilization/mix. H1 already &gt;50% of FY25 revenues (₹5,554 Cr).</td>
<td><strong>High</strong>: 20-30%+ revenue CAGR feasible; EBITDA 25%+ sustained.</td>
</tr>
</tbody>
</table>
<p><strong>Projected FY26</strong>: Revenues ~₹6,500-7,000 Cr (25-30% growth); EBITDA margins 23-26% (guided higher).</p>
</div>
<div id="key-risks" class="section level6">
<h6><strong>Key Risks</strong></h6>
<table>
<colgroup>
<col width="29%" />
<col width="25%" />
<col width="45%" />
</colgroup>
<thead>
<tr class="header">
<th>Risk Category</th>
<th>Description</th>
<th>Mitigation/Probability</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Execution/Operational</strong></td>
<td>Delays in capex (e.g., new facilities); CDMO lumpiness; capacity underutilization recurrence.</td>
<td>Medium – Track record strong; pipelines healthy.</td>
</tr>
<tr class="even">
<td><strong>Regulatory/Quality</strong></td>
<td>USFDA/WHO/EMA inspections (54 passed); 1,330+ audits. Pharma pricing/approvals delays.</td>
<td>Low-Medium – Recent audits clean; robust QMS.</td>
</tr>
<tr class="odd">
<td><strong>Financial/Leverage</strong></td>
<td>Capex-funded debt (1.3x EBITDA); forex volatility (exports heavy).</td>
<td>Low-Medium – Strong OCF covers; leverage declining.</td>
</tr>
<tr class="even">
<td><strong>Market/Competition</strong></td>
<td>CDMO competition (global players); Generics pricing pressure; ARV demand shifts.</td>
<td>Medium – Differentiated tech (flow/bio-catalysis); diversified pipeline.</td>
</tr>
<tr class="odd">
<td><strong>Macro/Geopolitical</strong></td>
<td>US/EU policy changes; raw material inflation; India land/mfg policy risks.</td>
<td>Medium – 68% Generics (ARV stable); multi-site ops.</td>
</tr>
<tr class="even">
<td><strong>Corporate</strong></td>
<td>NCLT delays on LSPL scheme; associate/JV performance (e.g., ImmunoACT, KRKA).</td>
<td>Low – Non-material.</td>
</tr>
</tbody>
</table>
<p><strong>Overall Summary</strong>: <strong>Strong Buy Case</strong> – Tailwinds dominate with exceptional H1 execution, CDMO leadership, and expansion pipeline positioning Laurus for multi-year growth (20-30% CAGR). Headwinds are capex-related but manageable with improving leverage/ROCE. Risks are pharma-typical (regulatory/execution) but mitigated by quality track record. Stock likely to re-rate on sustained margins (&gt;25% EBITDA) and FY26 beats. Monitor Q3 for capex absorption and CDMO inflows. Valuation: Attractive if trading &lt;30x FY26 EPS (~₹15-18 implied).</p>
<p><em>Analysis based solely on provided documents; real-time market data not considered.</em></p>
</div>
</div>
</div>
</div>

&nbsp;
&nbsp;
<hr />
<p style="text-align: center;">Copyright &copy; 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.</p>
<p style="text-align: center;"><a href="https://github.com/stockviz/reports/issues">&#x1F41E;</a></p>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
